NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- Lev Pharmaceuticals, Inc. today announced that it will conduct a conference call and audio web cast on Tuesday, November 13, 2007, at 1:00 p.m. Eastern Time (ET), in conjunction with the release of its financial results for the third quarter ended September 30, 2007. Lev anticipates releasing its financial results at 7:00 a.m. ET on Tuesday, November 13, 2007.
To access the live webcast, please click on the following link: http://phx.corporate-ir.net/playerlink.zhtml?c=130944&s=wm&e=1692330.
A replay of this webcast will be available for 30 days.
The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents at: www.streetevents.com, a password-protected event management site.
About Lev Pharmaceuticals, Inc.
Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev’s C1 inhibitor, to be marketed as Cinryze(TM), has been granted orphan drug status for the treatment and prevention of HAE, potentially securing, upon approval, market exclusivity for seven years. Lev has also received fast track designation status from the FDA, which facilitates the development and expedites the review of drugs and biologics intended to treat serious or life threatening conditions and that demonstrate the potential to address unmet medical needs. Lev is also evaluating the development of C1 inhibitor for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role.
jtuthill@levpharma.com
CONTACT: Jason Tuthill, Director, Investor Relations of Lev
Pharmaceuticals, Inc., +1-212-850-9130, jtuthill@levpharma.com
